alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2015398EN.01005202.xml

| 30.11.2015 | EN | Official Journal of the European Union | C 398/52 |
| --- | --- | --- | --- |

30.11.2015

EN

Official Journal of the European Union

C 398/52

---

Judgment of the General Court of 8 October 2015 — Société des produits Nestlé v OHIM (NOURISHING PERSONAL HEALTH)

(Case T-336/14) (1)

1

((Community trade mark - International registration designating the European Community - Word mark NOURISHING PERSONAL HEALTH - Absolute ground for refusal - No distinctive character - Article 7(1)(b) of Regulation (EC) No 207/2009 - Obligation to state reasons - Article 75 of Regulation No 207/2009 - Obligation on OHIM to examine the facts of its own motion - Article 76(1) of Regulation No 207/2009))

(2015/C 398/66)

Language of the case: English

Parties

Parties

Applicant: Société des produits Nestlé SA (Vevey, Switzerland) (represented by: A. Jaeger-Lenz, A. Lambrecht and S. Cobet-Nüse, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: Ó. Mondéjar Ortuño, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 12 March 2014 (Case R 149/2013-4) concerning the international registration designating the European Community of the word mark NOURISHING PERSONAL HEALTH.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Société des produits Nestlé SA to pay the costs. |
| --- | --- |

2.

Orders Société des produits Nestlé SA to pay the costs.

---

(1)  OJ C 261, 11.8.2014.

1

---
#### § 600.15 Temperatures during shipment.

The following products shall be maintained during shipment at the specified temperatures:

(a) *Products.*

| Product | Temperature |
| --- | --- |
| Cryoprecipitated AHF | −18 °C or colder. |
| Measles and Rubella Virus Vaccine Live | 10 °C or colder. |
| Measles Live and Smallpox Vaccine | Do. |
| Measles, Mumps, and Rubella Virus Vaccine Live | Do. |
| Measles and Mumps Virus Vaccine Live | Do. |
| Measles Virus Vaccine Live | Do. |
| Mumps Virus Vaccine Live | Do. |
| Fresh Frozen Plasma | −18 °C or colder. |
| Liquid Plasma | 1 to 10 °C. |
| Plasma | −18 °C or colder. |
| Platelet Rich Plasma | Between 1 and 10 °C if the label indicates storage between 1 and 6 °C, or all reasonable methods to maintain the temperature as close as possible to a range between 20 and 24 °C, if the label indicates storage between 20 and 24 °C. |
| Platelets | Between 1 and 10 °C if the label indicates storage between 1 and 6 °C, or all reasonable methods to maintain the temperature as close as possible to a range between 20 to 24 °C, if the label indicates storage between 20 and 24 °C. |
| Poliovirus Vaccine Live Oral Trivalent | 0 °C or colder. |
| Poliovirus Vaccine Live Oral Type I | Do. |
| Poliovirus Vaccine Live Oral Type II | Do. |
| Poliovirus Vaccine Live Oral Type III | Do. |
| Red Blood Cells (liquid product) | Between 1 and 10 °C. |
| Red Blood Cells Frozen | −65 °C or colder. |
| Rubella and Mumps Virus Vaccine Live | 10 °C or colder. |
| Rubella Virus Vaccine Live | Do. |
| Smallpox Vaccine (Liquid Product) | 0 °C or colder. |
| Source Plasma | −5 °C or colder. |
| Source Plasma Liquid | 10 °C or colder. |
| Whole Blood | Blood that is transported from the collecting facility to the processing facility shall be transported in an environment capable of continuously cooling the blood toward a temperature range of 1 to 10 °C, or at a temperature as close as possible to 20 to 24 °C for a period not to exceed 6 hours. Blood transported from the storage facility shall be placed in an appropriate environment to maintain a temperature range between 1 to 10 °C during shipment. |
| Yellow Fever Vaccine | 0 °C or colder. |

(b) *Exemptions.* Exemptions or modifications shall be made only upon written approval, in the form of a supplement to the biologics license application, approved by the Director, Center for Biologics Evaluation and Research.

[39 FR 39872, Nov. 12, 1974, as amended at 49 FR 23833, June 8, 1984; 50 FR 4133, Jan. 29, 1985; 50 FR 9000, Mar. 6, 1985; 55 FR 11013, Mar. 26, 1990; 59 FR 49351, Sept. 28, 1994; 64 FR 56449, Oct. 20, 1999]
RE .. r-.!f-'\·'E···o ~. · vt:.l v "": · 

U.S. DEPARTMENT OF TRANSPORTATION 

FEDERAL AVIATION ADMINISTRATION 

DEC 3 0 2015 

HEARING DOCKET 

In the matter of: 

Ridan Investments, Inc. 

JUDGE RICHARD C. GOODWIN 

) 

) 

) 

) 

FAA Docket No. FAA-2013-1082 

Case No. 2012S0720133 

NOTICE OF APPEARANCE 

Pursuant to 14 C.P.R.§ 13.204(a), Glenn H. Brown, 222 W 7

1

h Ave Box 14, Anchorage, 

AK 99513; telephone: 907-271-5271; hereby givesnotice of his appearance in this matter for 

Complainant Federal Aviation Administration. 

All future pleadings in this matter must be served on him and not the previously assigned 

attorney, Courtney Adolph. 

Dated this 18th day of December 2015. 

PeterJ.Lynch 

Assistant Chief Counsel 

for Enforcement 

By: 

Glenn H. Brown 

.Enforcement Division, Western Team 

222 W 7th Avenue Box 14 

Anchorage, AK 99513-7587 

email: glenn.brown@faa.gov 

telephone: (907) 271-5271 (direct) 

(907) 271-2800 (fax) 
CERTIFICATE OF SERVICE 

Re: Ridan Investments, Inc. 

FDMS No. FAA-2013-1082 

I hereby certify that on this date I have served a copy of the foregoing Notice of Appearance by 

postage-prepaid, certified mail, return receipt requested, to the following: 

The Honorable Richard C. Goodwin 

U.S. Administrative Law Judge 

Office of Hearings, M-20 

US Department of Transportation 

1200 New Jersey Avenue, S.E. (E11-310) 

Washington, DC 20590 

Fax: 202-366-7536 

Lawrence M. Burek, Respondent's Counsel 

Ridan Investments, Inc. 

550 North Parkcenter Drive, Ste. 204 

Santa Ana, CA 92705 

I further certify that on this date I have served the original and one copy of the foregoing Notice 

of Appearance by postage-prepaid, certified mail, return receipt requested and facsimile, 

addressed as follows: 

Federal Aviation Administration 

800 Independence Avenue, S.W. 

Washington, DC 20591 

ATTN: Hearing Docket Clerk, AGC-430 

Wilbur Wright Building-Suite 2W1 000 

Fax: (202) 493-5020 

DATED: 

Federal Aviation Administration 

Office of Regional Counsel 

222 West 7th Avenue, Box 14, AAL-7 

Anchorage, Alaska 99513-7587 

2
# C_2021252EN.01003402.xml

| 28.6.2021 | EN | Official Journal of the European Union | C 252/34 |
| --- | --- | --- | --- |

28.6.2021

EN

Official Journal of the European Union

C 252/34

---

Order of the General Court of 5 May 2021 — Anastasiou v Commission and ECB

(Case T-149/14) (1)

(2021/C 252/46)

Language of the case: English

The President of the First Chamber, Extended Composition has ordered that the case be removed from the register.

---

(1)  OJ C 159, 26.5.2014.

---
# C_2014339EN.01000201.xml

| 29.9.2014 | EN | Official Journal of the European Union | C 339/2 |
| --- | --- | --- | --- |

29.9.2014

EN

Official Journal of the European Union

C 339/2

---

Request for a preliminary ruling from the Tribunale Amministrativo Regionale per il Lazio (Italy) lodged on 30 June 2014 — Confederazione Generale Italiana del Lavoro (CGIL), Istituto Nazionale Confederale Assistenza (INCA) v Presidenza del Consiglio dei Ministri, Ministero dell’Interno, Ministero dell’Economia e delle Finanze

(Case C-309/14)

2014/C 339/02

Language of the case: Italian

Referring court

Referring court

Tribunale Amministrativo Regionale per il Lazio

Parties to the main proceedings

Parties to the main proceedings

Applicants: Confederazione Generale Italiana del Lavoro (CGIL),

Applicants:

Istituto Nazionale Confederale Assistenza (INCA)

Defendants: Presidenza del Consiglio dei Ministri,

Defendants:

Ministero dell’Interno,

Ministero dell’Economia e delle Finanze

Question referred

Question referred

Do the principles laid down in Council Directive 2003/109/EC (1) as subsequently amended and supplemented, preclude rules of national law, such as those laid down in Article 5(2-ter) of Legislative Decree No 286 of 25 July 1998, in that they provide that ‘the application for the issue and the renewal of the residence permit shall be subject to the payment of a fee, the amount of which shall be set at a minimum of EUR 80 and a maximum of EUR 200 by joint decree of the Ministry of the Economy and Finance and of the Ministry of the Interior which shall also lay down the conditions for the payment ...’ thereby fixing a minimum amount for the fee equal to around eight times the charge for the issue of a national identity card?

1

---

(1)  Council Directive 2003/109/EC of 25 November 2003 concerning the status of third-country nationals who are long-term residents (OJ 2004 L 16, p. 44).

1

---
<PAGE>

                                                              EXHIBIT 10.4

                           (Price Edwards & Company Logo)
                                   Oklahoma Tower
                            210 Park Avenue, Suite 1000
                              Oklahoma City, OK  73102
                          405/843-7474 -- FAX 405/840-2137

May 9, 1996


Mr. Michael McDonald
UroCor Corporation
800 Research Parkway
Suite 200
Oklahoma City, OK  73104

Dear Mike:

In reviewing your lease document, it appears that any space in excess of 50,000 
rentable square feet should be billed back to you at $10.00 per square foot 
during the first year of your lease agreement.  We have measure that your 
rentable square feet should be as follows:
   1st Floor     2,283
   2nd Floor    22,800
   3rd Floor    25,975
                ------
                51,058
                ------
                ------

Based upon our phone conversation of yesterday, it is agreed that this excess 
space became effective January 1, 1996.  In that these measurements exceed 
50,000 square feet by 1,058 square feet and we have been charging for base 
rent only, we are now billing you for excess rent on 1,058 square feet at 
$10.00 per square foot, calculated as follows:

             1,058  excess rentable square feet
           $ 10.00  per square foot
           -------
           $10,580  
               365  
           -------
           $ 28.99  per diem
           x   121  day occupied (1/01/96 through 4/30/96)
           -------
        $ 3,507.79
        ----------
        ----------
  
We will also adjust your monthly rent by $881.67 beginning with your May 
billing.

Should you have any questions, please contact me.

Sincerely,

/s/ James J. Fiedler
------------------------
Vice President
Accounting and Reporting

JJF/kka

cc: Randy Hogan
 Dennis McGrath
IN THE

TENTH COURT OF APPEALS

No. 10-21-00079-CV

WILBERT NORWOOD STARKS,

Appellant

v.

DAWSON INDEPENDENT SCHOOL DISTRICT, 

NAVARRO COUNTY, AND 

NAVARRO COLLEGE,

Appellees

From the 13th District Court

Navarro County, Texas

Trial Court No. D 48685-TX

MEMORANDUM OPINION

Wilbert Norwood Starks’s notice of appeal was filed on April 1, 2021. In a letter 

dated April 15, 2021, the Clerk of this Court notified Starks that the appeal was subject to 

dismissal because it appeared the notice of appeal was untimely. The trial court’s 

Judgment in this case was signed on October 30, 2020. Starks’s notice of appeal was due 

November 30, 2020. See TEX. R. APP. P. 26.1.

In the same letter, Starks was also warned that the Court would dismiss the appeal 
Starks v. Dawson I.S.D., et al. Page 2

without further notification unless, within 14 days from the date of the letter, a response 

was filed showing grounds for continuing the appeal. Starks timely responded but did 

not show grounds for continuing the appeal. 

Accordingly, this appeal is dismissed for want of jurisdiction.

TOM GRAY

Chief Justice

Before Chief Justice Gray,

Justice Neill, and

Justice Johnson

Appeal dismissed

Opinion delivered and filed May 12, 2021

[CVO6]
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7360 Erythrocytic glucose-6-phosphate dehydrogenase assay. ( a ) *Identification.* An erythrocytic glucose-6-phosphate dehydrogenase assay is a device used to measure the activity of the enzyme glucose-6-phosphate dehydrogenase or of glucose-6-phosphate dehydrogenase isoenzymes. The results of this assay are used in the diagnosis and treatment of nonspherocytic congenital hemolytic anemia or drug-induced hemolytic anemia associated with a glucose-6-phosphate dehydrogenase deficiency. This generic device includes assays based on fluorescence, electrophoresis, methemoglobin reduction, catalase inhibition, and ultraviolet kinetics.
( b ) *Classification.* Class II (performance standards).
[45 FR 60616, Sept. 12, 1980]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3085 *Brucella* spp. serological reagents. ( a ) *Identification. Brucella* spp. serological reagents are devices that consist of antigens and antisera used for serological identification of *Brucella* spp. from cultured isolates derived from clinical specimens or to identify antibodies to *Brucella* spp. in serum. Additionally, some of these reagents consist of antisera conjugated with a fluorescent dye (immunofluorescent reagents) used to identify *Brucella* spp. directly from clinical specimens or cultured isolates derived from clinical specimens. The identification aids in the diagnosis of brucellosis (e.g., undulant fever, Malta fever) caused by bacteria belonging to the genus *Brucella* and provides epidemiological information on diseases caused by these microorganisms.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 63 FR 59226, Nov. 3, 1998]
I 

118TH CONGRESS 

2D SESSION H. R. 7816 

To direct the Secretary of Veterans Affairs to seek to enter into an agreement 

with a federally funded research and development center for an assessment of notice letters that the Secretary sends to claimants for benefits 

under laws administered by the Secretary, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 26, 2024 

Mr. DUARTE (for himself, Mr. BOST, Mr. VALADAO, Ms. SALAZAR, Mr. 

D’ESPOSITO, and Ms. BUDZINSKI) introduced the following bill; which 

was referred to the Committee on Veterans’ Affairs 

A BILL 

To direct the Secretary of Veterans Affairs to seek to enter 

into an agreement with a federally funded research and 

development center for an assessment of notice letters 

that the Secretary sends to claimants for benefits under 

laws administered by the Secretary, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Clear Communication 

5 for Veterans Claims Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7816 IH

1 SEC. 2. INDEPENDENT ASSESSMENT OF NOTICES THAT THE 

2 SECRETARY OF VETERANS AFFAIRS SENDS 

3 TO CLAIMANTS. 

4 (a) AGREEMENT.—Not later than 30 days after the 

5 date of the enactment of this Act, the Secretary of Vet6 erans Affairs shall seek to enter into an agreement with 

7 an FFRDC for an assessment of notices that the Sec8 retary sends to claimants. 

9 (b) ASSESSMENT.—An FFRDC that enters to an 

10 agreement under subsection (a) shall submit to the Sec11 retary a written assessment of such notices. The assess12 ment shall include the following: 

13 (1) The determination of the FFRDC whether 

14 each such notice may be feasibly altered to reduce 

15 paper consumption by, and costs to, the Federal 

16 Government. 

17 (2) The recommendations of the FFRDC re18 garding how the Secretary may, in compliance with 

19 laws administered by the Secretary, make such no20 tices clearer to claimants, better organized, and 

21 more concise. 

22 (c) REPORT; IMPLEMENTATION.—Not later than 90 

23 days after the Secretary receives the assessment under 

24 subsection (b), the Secretary shall— 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•HR 7816 IH

1 (1) submit to the Committees on Veterans’ Af2 fairs of the Senate and House of Representatives a 

3 copy of such assessment; and 

4 (2) implement the recommendations in the as5 sessment. 

6 (d) DEFINITIONS.—In this section: 

7 (1) The term ‘‘FFRDC’’ means a federally 

8 funded research and development center. 

9 (2) The terms ‘‘claimant’’ and ‘‘notice’’ have 

10 the meanings given such terms in section 5100 of 

11 title 38, United States Code. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
Exhibit 10.13
                                                                   -------------

                  [Letterhead of Euro Brokers Finacor Limited]



PRIVATE AND CONFIDENTIAL
------------------------
Mr R. Clark
1 Ottley Place
Margaretting
Essex
CM4 9QE

Ref: LF/I/P/L/RAC011002

1 October 2002


Dear Robin,

I refer to your contract of employment dated 1 October 2000 (the "Contract") and
write to confirm our agreement to a variation of the terms of the Contract as
follows:

With immediate effect, the minimum term under Clause 2.1 of the Contract shall
be extended until 30 September 2006 ("the Minimum Term") so that the Contract
may be terminated by either party giving six months notice in writing to expire
at any time on or after expiry of the Minimum Term.

With effect from 1 October 2002 the fixed annual salary payable to you under
Clause 3.1 of your Contract was increased to (pound)400,000.

The provisions of sub-clauses 2.2 and 2.3 shall be deleted in their entirety and
replaced with the following wording:

2.2   Provided always that in the event of the Company suffering a Change of
      Control you shall, with effect from the effective date of such Change of
      Control, be entitled if the Company does not at such time make provision
      to assign this Agreement to another Group Company that is still controlled
      by Maxcor Financial Group Inc. ("Maxcor"), at any time thereafter to
      terminate this Agreement by giving to the Company four months notice in
      writing. For the avoidance of doubt, any Change of Control shall not in
      any way affect the relevant notice the Company may be required to give to
      you in order to terminate this Agreement.

2.3   For the purposes of this clause "Change of Control" means the acquisition
      by any person (or any combination thereof acting together) of the power to
      secure directly whether by contract, voting rights or otherwise that the
      affairs of the Company are conducted in accordance with the wishes of that

<PAGE>

      person, such person being a person who did not previously have control and
      is not a subsidiary of either of the Company or Maxcor. For the avoidance
      of doubt, an indirect change of control of the Company through a Change of
      Control of Maxcor shall not be deemed a Change of Control of the Company
      hereunder."


For the avoidance of doubt, all other terms shall remain in full force and
effect.


THIS CONSTITUTES A VARIATION OF YOUR CONTRACT OF EMPLOYMENT. Accordingly, please
confirm your agreement to this amendment by signing and returning the enclosed
copy of this letter to personnel, as soon as possible.

Yours sincerely,


/s/ WILLIAM PASK
-----------------------------
William Pask
Finance Director


I hereby agree to the above variation to the terms and conditions of my
employment.


Signed  /s/ ROBIN CLARK                    Date          10/10/02
        ----------------------------------       ------------------------------
================================================================================

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                   ----------

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                         Date of Report: April 24, 2003

                               i-STAT Corporation
                               ------------------

             (Exact name of registrant as specified in its charter)

           Delaware                      0-19841                  22-2542664
           --------                      -------                  ----------
(State or other jurisdiction of        (Commission            (I.R.S. Employer
incorporation or organization)         file number)          Identification No.)

                104 WINDSOR CENTER DRIVE, EAST WINDSOR, NJ 08520
               (Address of principal executive offices) (Zip code)

                                 (609) 443-9300
              (Registrant's telephone number, including area code)

================================================================================
<PAGE>

Item 5. Other Events and Regulation FD Disclosure

      On April 24, 2003, the Company issued a press release disclosing its
financial results for the first quarter of 2003. The full text of the press
release is set forth in Exhibit 99.1 which is attached hereto and is
incorporated by reference into this report.

Item 7. Exhibits.

(c) Exhibits

Item No.    Exhibit List

99.1        First Quarter 2003 earnings press release dated April 24, 2003.
<PAGE>

                                    SIGNATURE
                                    ---------

      Pursuant to the requirements of the Securities Exchange Act of 1934,
i-STAT Corporation has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                           i-STAT  CORPORATION
                                           By:
                                           /s/ LORIN J. RANDALL
                                           -------------------------------------
                                           Lorin J. Randall
                                           Senior Vice President of Finance,
                                           Treasurer and Chief Financial Officer

Date: April 24, 2003